Cat. No. | Product name | CAS No. |
DCC4241 |
prmt3 Inhibitor 1
Allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) |
1340875-03-7 |
DCC4242 |
prmt3 Inhibitor 14u
Potent and selective inhibitor of protein arginine methyltransferase 3 (PRMT3) |
|
DCC4243 |
Prmt4-in-1
Novel potent and selective inhibitor of PRMT4 (also known as CARM1) |
|
DCC4244 |
Prmt5-in-4b14
Novel potent PRMT5 inhibitor, exhibiting potent anti-proliferative activity against a panel of leukemia and lymphoma cells |
|
DCC4245 |
Prmt5-in-c17
Featured
Novel potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor |
330951-01-4 |
DCC4246 |
Prmts Inhibitor A36
Potent inhibitor of protein arginine methyltransferases (PRMTs) |
318263-94-4 |
DCC4247 |
Prmts Inhibitor A9
Potent inhibitor of protein arginine methyltransferases (PRMTs) |
380652-58-4 |
DCC4248 |
Prn1008
Novel, Reversible Covalent BTK Inhibitor for Rheumatoid Arthritis |
1575596-77-8 |
DCC4249 |
Prn1126
Novel reversible covalent selective LMP7 inhibitor |
|
DCC4250 |
pr-nhp5g
Antagonist at the NR1/NR2A subtype but an agonist at the NR1/NR2D subtype |
1040283-99-5 |
DCC4251 |
Probimane
Potent inhibitor of tumor metastasis, inhibiting calmodulin, sialic acid, lipoperoxidation, fibrinogen, cell-movement and the cell-cycle arrest |
108093-90-9 |
DCC4252 |
Procaspase-8 Inhibitor 63-r
Novel selective procaspase-8 (Pro-C8) Inhibitor covalently binding the zymogen, or inactive precursor (pro-form), of caspase-8, but not other caspases |
|
DCC4253 |
Pro-nbdhex
Prodrug of NBDHEX, selectively inhibiting glutathione transferase (GST P1-1) with better water solubility, and more potent anticancer activities |
|
DCC4254 |
Protac 14a
Novel potent cereblon degrader with DC50 of 200 nM, and 64% protein degradation, as quantified by western blot |
2358775-70-7 |
DCC4256 |
Protac Cp17
Novel highly potent degrader against EGFRL858R/T790M and EGFRdel19, reaching the lowest DC 50 values among all reported EGFR-targeting PROTACs |
|
DCC4257 |
Protac D9a-2
Novel SLC-targeting chimeric degrader, targeting SLC9A1 and other SLC9 family members, effectively impairing pH homeostasis and differentially killing cancer cell lines |
|
DCC4258 |
Protac Degrader Pp-c8
Novel noncovalent CDK12/13 dual inhibitor, inducing potent and selective CDK12-CycK degradation without affecting CDK13, suppressing DDR-associated genes and induced synthetic lethality with Olaparib |
|
DCC4259 |
Protac Hl-8
Novel PI3K degrader, showing a significant and complete degradation effect on PI3K kinase at a concentration of 10 μM within 8 h |
|
DCC4260 |
Protac Nr-7h
Novel potent and selective p38α and p38β degrader |
|
DCC4261 |
Protac P22a
Novel degrader of HMGCR protein, potently blocking cholesterol biosynthesis with less compensatory upregulation of HMGCR |
|
DCC4262 |
Protac P3
Novel potent epidermal growth factor receptor (EGFR) degrader, inducing EGFRdel19 and EGFRL858R/T790M degradation with DC50 values of 0.51 and 126 nM, showing potent anti-proliferative activity against HCC827 and H1975 cell lines with IC50 values of 0.83 |
|
DCC4263 |
Protac(h-pgds)-1
Novel potent degrader of H-PGDS protein via the ubiquitin-proteasome system and in the suppression of prostaglandin D2 (PGD2) production |